Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03290248 · ClinicalTrials.gov registry record · Phase 1

Study to Assess the Safety, Tolerability, and Preliminary Efficacy of B244 in Healthy Volunteers and Subjects With Seasonal Allergic Rhinitis

A Phase 1 study, sponsored by AOBiome.

Completed
Registry status
Phase 1
Development phase
71
Enrollment target

NCT03290248 is a Phase 1 study that has completed, run by AOBiome. The registered enrollment target is 71 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03290248, a Phase 1 study, has completed, sponsored by AOBiome.

COMPLETED
Registry status
Phase 1
Development phase
71 participants
Enrollment target

Study Summary

This is a Prospective, Controlled, Double Blinded, Single Center, Randomized, 3 Arm, Parallel Assignment, Phase 1b/2a Study to assess the safety, tolerability, and preliminary efficacy of B244 delivered as an intranasal spray in healthy volunteers and subjects with seasonal allergic rhinitis.

Interventions

  • BIOLOGICAL Vehicle
  • BIOLOGICAL B244 suspension

Trial Details

FieldValue
Enrollment Target 71 participants
Start Date 2017-09-19
Est. Completion 2018-12-21
Phase Phase 1

Sponsor

AOBiome

11 total trials

What the Registry Record Tells You About NCT03290248

The ClinicalTrials.gov registry entry for NCT03290248 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 71 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AOBiome, which has 11 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Vehicle is the first listed.

NCT03290248 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT03290248 about?

NCT03290248 is a clinical study titled "Study to Assess the Safety, Tolerability, and Preliminary Efficacy of B244 in Healthy Volunteers and Subjects With Seasonal Allergic Rhinitis". This is a Prospective, Controlled, Double Blinded, Single Center, Randomized, 3 Arm, Parallel Assignment, Phase 1b/2a Study to assess the safety, tolerability, and preliminary efficacy of B244 delivered as an intranasal spray in healthy volunteers and subjects with seasonal allergic rhinitis.

What is the current status of trial NCT03290248?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 71 participants. The study started on 2017-09-19. Estimated completion is 2018-12-21.

What interventions are being tested in trial NCT03290248?

The interventions under investigation include: Vehicle (BIOLOGICAL), B244 suspension (BIOLOGICAL).

Who is sponsoring clinical trial NCT03290248?

This trial is sponsored by AOBiome, which has 11 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.